00:32 , Jun 17, 2016 |  BC Extra  |  Company News

Management tracks

Immunotherapy company Hookipa Biotech AG (Vienna, Austria) named Joern Aldag CEO. He was CEO of uniQure N.V. (NASDAQ:QURE). Cancer company Aprea AB (Solna, Sweden) named Christian Schade president and CEO. He was CEO of Novira...
07:00 , May 16, 2016 |  BC Week In Review  |  Company News

Cynata, apceth deal

apceth gained an option to license worldwide rights to develop Cynata’s Cymerus mesenchymal stem cells (MSC) engineered with apceth’s genetic modification technology to treat cancer and other diseases. apceth expects to complete an initial evaluation...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Company News

apceth, University of Cologne deal

apceth partnered with the university’s Center for Molecular Medicine Cologne to develop immunotherapies to treat solid tumors and hematological malignancies. The partners will combine CAR T cells against multiple undisclosed tumor-associated antigens developed at the...
01:50 , Apr 24, 2015 |  BC Extra  |  Company News

Management tracks

Royalty play Ligand Pharmaceuticals Inc. (NASDAQ:LGND) said CFO Nishan de Silva resigned effective May 20. Melanie Herman, Ligand's director of accounting and chief accounting officer, will be interim CFO. Renal therapeutic company Keryx Biopharmaceuticals Inc....
08:00 , Feb 3, 2014 |  BC Week In Review  |  Clinical News

Agenmestencel-T: Phase I/II started

Apceth began the European Phase I/II TREAT ME trial to evaluate IV agenmestencel-T in about 28 patients. Apceth GmbH & Co. KG , Munich, Germany   Product: Agenmestencel-T , MSC_apceth_101   Business: Cancer   Molecular...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Apceth management update

Apceth GmbH & Co. KG , Munich, Germany   Business: Gene/Cell therapy   Hired: Stefanos Theoharis as CBO, a newly created position, formerly head of business development at Antisense Pharma GmbH  ...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Agenmestencel-T: Phase I/II start

This month, Apceth will begin an open-label, German Phase I/II trial to evaluate agenmestencel-T in 28 patients. Apceth GmbH & Co. KG , Munich, Germany   Product: Agenmestencel-T , MSC_apceth_101   Business: Cancer   Molecular...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Company News

Apceth, Indivumed deal

The companies partnered to use Indivumed's tumor tissue bank to develop a tissue-based biomarker platform to predict the response of a targeted cellular/gene therapy in different cancer types and to stratify patients. The parties said...
07:00 , Oct 17, 2011 |  BC Week In Review  |  Company News

Apceth management update

Apceth GmbH & Co. KG , Munich, Germany   Business: Gene/Cell therapy   Hired: Ralf Huss as chief scientific officer, formerly global head of therapeutic cell initiative at Roche  ...
07:00 , Sep 5, 2011 |  BC Week In Review  |  Clinical News

MSC_Apceth: Phase I/II started

Apceth began an open-label, German Phase I/II trial to compare percutaneous transluminal angioplasty followed by infusion of MSC_Apceth vs. percutaneous transluminal angioplasty alone in 30 patients. Apceth GmbH & Co. KG , Munich, Germany  ...